No business profile yet.
Size Handa Pharmaceuticals (6620.TWO) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $469M, the 450th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$101.50 on 18 Nov 2026.
Performance Over six months the shares gained 45.0%, against -9.3% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth Revenue fell 15.9% over the last twelve months (peer median +13.0%); the operating margin is 29.8% (peer median 0.1%).
Valuation It trades at 24.9× forward earnings against a peer median of 25.9× (3rd cheapest of 5).
Price implies For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is +127%, so the hurdle is -102 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.9 points below its cost of capital (6.3% WACC).
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$930M | NT$1.73B | NT$831M | NT$1.11B | NT$198M |
| Revenue growth | — | +108% | -25% | +460% | — |
| Gross profit | NT$881M | NT$1.45B | NT$819M | NT$1.09B | NT$164M |
| EBITDA | n/a | NT$1.10B | NT$428M | NT$706M | -NT$72.9M |
| Net income | NT$298M | NT$750M | NT$473M | NT$727M | -NT$40.0M |
| Free cash flow | n/a | NT$227M | NT$490M | NT$667M | -NT$212M |
| Capital expenditure | n/a | NT$17.1M | NT$7.77M | NT$944,000 | NT$758,000 |
| Total debt | n/a | NT$47.6M | NT$40.1M | NT$13.2M | NT$29.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6620.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -29.3% | -2.1% | lowest of 21 |
| 6-month return | +45.0% | -9.3% | 3rd highest of 20 |
| Distance from 52-week high | -34.5% | -39.2% | 9th highest of 21 |
| Revenue growth (TTM) | -15.9% | +13.0% | 2nd lowest of 20 |
| Operating margin | 29.8% | 0.1% | highest of 19 |
| Forward P/E | 24.9× | 25.9× | 3rd cheapest of 5 |
| Growth the price implies (Req g, 7 yrs) | 24.8% | 3.9% | 2nd most demanding of 7 |
| Growth delivered (Del g) | +126.7% | +2.1% | highest of 7 |
| Hurdle (Req g minus delivered) | -101.9 pp | +0.5 pp | 2nd least demanding of 7 |
| ROIC minus cost of capital | -1.9 pp | -5.4 pp | 8th highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Handa Pharmaceuticals 6620.TWO | Taiwan | $469M | +45% | -16% | 30% | 24.9× | 24.8% | +126.7% |
| Evolus EOLS | United States | $468M | +7% | +14% | -5% | 28.5× | n/a | n/a |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $468M | -32% | -4% | -11% | n/a | n/a | n/a |
| Capricor Therapeutics CAPR | United States | $467M | -70% | -100% | n/a | n/a | n/a | n/a |
| Kwality Pharmaceuticals KPL.NS | India | $467M | +110% | +48% | 22% | n/a | n/a | n/a |
| ChengDa PharmaCeuticals 301201.SZ | China | $472M | -47% | +27% | -9% | n/a | n/a | n/a |
| YungShin Global 3705.TW | Taiwan | $472M | +5% | -5% | 15% | n/a | -3.8% | +0.7% |
| Hainan Shuangcheng Pharmaceuticals 002693.SZ | China | $465M | -28% | +40% | 13% | n/a | 44.1% | +1.0% |
| BlossomHill Therapeutics BLSM | United States | $464M | n/a | n/a | n/a | n/a | n/a | n/a |
| Aquestive Therapeutics AQST | United States | $475M | -9% | +13% | -114% | n/a | n/a | n/a |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $477M | +16% | +13% | 16% | 42.2× | n/a | n/a |
| Shanghai Fudan Forward S&T 600624.SS | China | $478M | 0% | -14% | -34% | n/a | n/a | n/a |
| Hansa Biopharma HNSA.ST | Sweden | $479M | +39% | +69% | -190% | n/a | -4.7% | +105.3% |
| Assembly Biosciences ASMB | United States | $458M | -15% | +80% | -32% | n/a | n/a | n/a |
| REGENXBIO RGNX | United States | $480M | +22% | -5% | -120% | n/a | n/a | n/a |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $481M | -8% | +23% | -61% | n/a | n/a | n/a |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $486M | -21% | -1% | 10% | 18.2× | n/a | n/a |
| Gufic Biosciences GUFICBIO.NS | India | $452M | +48% | +17% | 14% | n/a | n/a | n/a |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $487M | -29% | +32% | 17% | n/a | 3.3% | -1.1% |
| Newland Pharmaceutical 301277.SZ | China | $488M | -22% | +9% | 11% | n/a | 8.9% | +9.1% |
| Pulike Biological Engineering 603566.SS | China | $449M | -21% | -9% | 5% | 23.2× | 4.5% | +3.3% |